Oscar Health, Inc. (OSCR) received an upgrade to an “Overweight” rating from Jessica Tassan at Piper Sandler on November 26, 2025, indicative of growing confidence in the company’s performance amidst challenging market conditions. This strategic shift comes as investors are evaluating the stock’s current price of $16.73 against a new price target of $25, suggesting a potential upside that could attract both cautious and aggressive investors.
Recent Price Action
In the wake of the upgrade, OSCR’s stock has shown notable movement, closing recently at $16.73, with a weekly gain of approximately 7.59%. This rise is particularly significant given that the stock has wrestled with considerable volatility, reflected in a 52-week range that has seen a high of $49.37 and a low of $16.73. With a trading volume of over 9.23 million shares, significantly lower than the average volume of 17.39 million, investor activity appears to be consolidating around this new price level. The beta of 1.878 further underscores the stock’s volatility, reinforcing its potential for both high rewards and substantial risks.
Short- and Long-Term Performance
Examining OSCR’s performance across various timeframes reveals a mixed picture. Over the past 30 days, the stock has declined by 13.73%, reflecting a challenging environment for growth-oriented equities. However, a recovery appears to have begun in the last quarter, where the stock posted a quarterly performance of 13.52%. Over the past year, OSCR has struggled, resulting in a slight loss of 2.05%. Recent volatility rates have been high, with weekly volatility at 6.55% and monthly volatility reaching 7.55%, indicating a turbulent trading environment that may concern conservative investors.
Earnings Analysis
Oscar Health’s most recent earnings report, released on November 6, 2025, indicated an earnings per share (EPS) of -$0.54, slightly better than the estimated figure of -$0.55, suggesting a degree of resilience despite ongoing challenges. Comparing this to the previous quarter, where the EPS was reported at -$0.89 against an estimate of -$0.90, the small but positive surprise of 2.16% demonstrates some improvement in the company’s financial health. This performance could signal to investors that Oscar Health might be on a path toward recovery, even if it remains in negative territory.
Analyst / Consensus View
The broader analyst sentiment surrounding OSCR remains cautionary yet intrigued. According to a consensus analysis over the past 90 days, there are a total of six ratings on the stock, with one “Buy,” one “Hold,” and four “Sell” ratings. The average price target stands at $15.33, with a low target of $11 and a high target of $25—indicative of the divergent opinions held by analysts. The recent upgrade by Piper Sandler highlights a specific bullish perspective amidst the prevailing cautious sentiment, suggesting a potentially lucrative entry point for some investors.
Stock Grading or Fundamental View
The Stocks Telegraph Score for Oscar Health currently stands at 44, illustrating a blend of both challenges and opportunities within the company. While the score reflects some underlying strengths, such as market presence and potential upside, it also indicates an elevated level of risk and the need for careful evaluation of the company’s long-term strategies and operational improvements.
Conclusion
For investors contemplating Oscar Health, Inc. (OSCR), the stock presents a compelling, albeit risky, opportunity. With an “Overweight” rating and a significant upside target, it may attract those with a higher risk tolerance looking for growth potential in a volatile market. However, prospective investors should remain alert to the inherent risks, especially given the company’s history of negative earnings and market challenges. Overall, while Oscar Health presents a tantalizing opportunity for long-term growth, it is essential for investors to conduct thorough due diligence, weighing the potential for recovery against the existing uncertainties that have marked its recent performance.